Study of Serum Amylase and Serum Creatinine in Subclinical Hypothyroidism

Abstract Introduction: Subclinical hypothyroidism (SCH) can be defined as a state of high serum thyroid stimulating hormone (TSH) levels (less than 10 μIU/ml) with normal serum free thyroxine (fT4) and triiodothyronine (fT3) levels in the presence or absence of symptoms. SCH is confirmed by laboratory diagnosis of serum picture of elevated thyroid stimulating hormone (TSH) and normal serum concentration of free thyroxine (fT4) and total Triiodothyronine (T3). The aim to this study was to determine levels of Serum Amylase, Serum Creatinine in Subclinical Hypothyroidism. Material and Method: An observational cross-sectional study was conducted between November 2023 and October 2024, involving participants with and without Subclinical Hypothyroidism. Blood samples were analysed for serum amylase, creatinine levels to assess biochemical variations. Clinical data was collected from hospital records. Result: 260 participants, 130 with subclinical Hypothyroidism and 130 healthy controls were recruited. The level of Serum Amylase increased from 60U/L in controls to 90.28 U/L in cases. (p<0.001). Similarly, the level of Serum Creatinine increased from 0.77 mg% to 1.06 mg% (p<0.001). Conclusion: According to findings of the study there is significant change in levels of Serum Amylase, Serum Creatinine in Healthy Controls and Subclinical Hypothyroidism showing a need for early detection and proper screening to prevent the progress of disease to adverse conditions.